Shyamkishore Shrivastava|Umesh Mahantshetty|Reena Engineer|Supriya Chopra|Ranjana Hawaldar|Vinod Hande|Rajendra Kerkar|Amita Maheshwari|TS Shylasree|Jaya Ghosh|Jyoti Bajpai|Lavanya Gurram|Seema Gulia|Sudeep Gupta
Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix
Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital|Homi Bhabha National Institute|Tata Memorial Hospital
evidence concurrent chemoradiotherapy ctrt international federation gynecology obstetrics figo stage iiib squamous cell carcinoma uterine cervix robust study reports final results randomized clinical trial concurrent cisplatinbased ctrt radiotherapy alone rt women figo stage iiib squamous cell carcinoma uterine cervixto investigate benefit concurrent ctrt figo stage iiib squamous cell carcinoma uterine cervixthis phase 3 openlabel randomized clinical trial accrued 850 women mumbai india july 7 2003 september 22 2011 2121 screened 850 women figo stage iiib squamous cell carcinoma uterine cervix suitable concurrent cisplatin chemotherapy randomly assigned ctrt rt using block randomization 11 data updated minimum followup period 5 years december 2016 final analyses performed february march 2017 singleinstitution study conducted tertiary cancer center settingrandomization receive rt rt arm comprising combination external beam rt 50 gy 25 fractions 5 weeks brachytherapy receive addition rt concurrent weekly cisplatin chemotherapy 40 mgm2 per week ctrt armthe primary end point 5year diseasefree survival dfs defined time date randomization date recurrence death whichever occurred first intenttotreat populationthis trial included 424 women assigned ctrt mean sd age 494 79 years 426 women assigned rt mean sd age 493 79 years median followup 88 months interquartile range 6131131 months 222 recurrences 213 deaths ctrt arm 252 recurrences 243 deaths rt arm 5year dfs significantly higher ctrt arm 523 95 ci 522524 compared rt arm 438 95 ci 437439 hazard ratio relapse death 081 95 ci 068098 p 03 similarly 5year overall survival os significantly higher ctrt arm 540 95 ci 539541 compared rt arm 460 95 ci 459461 hazard ratio death 082 95 ci 068098 p 04 adjusting prognostic factors ctrt continued significantly superior rt dfs os higher incidence acute hematological adverse effects ctrt armchemoradiotherapy using weekly cisplatin results significantly better dfs os compared rt women stage iiib squamous cell carcinoma uterine cervix study provides level 1 evidence largest clinical trial reported far favor concurrent weekly cisplatin chemotherapy settingclinicaltrialsgov identifier nct00193791